Current Neuro-Oncology
Volume
11 Number 2
28 February 2009
Home > Publications > Current Neuro-Oncology > Volume 11, Year 2009 > Number 2, 28 February
Quinn JA, Jiang SX, Carter J,
Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S,
Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd,
Threatt S, Friedman HS.
Phase
II trial of Gliadel plus O6-benzylguanine in adults with recurrent
glioblastoma multiforme.
Clin
Cancer Res. 2009
Feb 1;15(3):1064-8. doi:
10.1158/1078-0432.CCR-08-2130. PMID:
19188181. Interventional study. ˍ
Brandes AA, Tosoni A, Franceschi E,
Sotti G, Frezza G, Amistà P, Morandi L, Spagnolli F, Ermani
M.
Recurrence
pattern after temozolomide concomitant with and adjuvant to
radiotherapy in newly diagnosed patients with glioblastoma:
correlation With MGMT promoter methylation status.
J
Clin Oncol. 2009
Feb 2;27(8):1275-9. doi:
10.1200/JCO.2008.19.4969. PMID:
19188675. Observational study. ˍ
*
Glas M, Happold C, Rieger J,
Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD,
Reifenberger G, Weller M, Herrlinger U.
Long-term
survival of patients with glioblastoma treated with radiotherapy
and lomustine plus temozolomide.
J
Clin Oncol. 2009
Feb 2;27(8):1257-61. doi:
10.1200/JCO.2008.19.2195. PMID:
19188676. Observational study. ˍ
Read TA, Fogarty MP, Markant SL,
McLendon RE, Wei Z, Ellison DW, Febbo PG, Wechsler-Reya RJ.
Identification
of CD15 as a marker for tumor-propagating cells in a mouse model
of medulloblastoma.
Cancer
Cell. 2009 Feb
3;15(2):135-47. doi:
10.1016/j.ccr.2008.12.016. PMID:
19185848. Laboratory investigation. ˍ
Erratum
in: Cancer
Cell.
2009 Sep 8;16(3):267. doi:
10.1016/j.ccr.2009.08.009. Correction. ˍ
Chamberlain MC, Johnston
S.
Bevacizumab
for recurrent alkylator-refractory anaplastic
oligodendroglioma.
Cancer.
2009 Feb 5;115(8):1734-43. doi:
10.1002/cncr.24179. PMID:
19197992. Observational study. ˍ
Schröter S, Halatsch ME,
Behnke-Mursch J, Mursch K.
Self-help
activities of brain tumour patients and their relatives.
Cent
Eur Neurosurg.
2009 Feb 5;70(1):21-6. doi:
10.1055/s-0028-1087215. PMID:
19197831. Observational study. ˍ
Steiger HJ, Göppert M, Floeth
F, Turowski B, Sabel M.
Fronto-mesial
WHO grade II and III gliomas: specific aspects of tumours arising
from the anterior cingulate gyrus.
Acta
Neurochir (Wien).
2009 Feb 5;151(2):137-40. doi:
10.1007/s00701-008-0160-x. PMID:
19194655. Observational study. ˍ
Yaman E, Coskun U, Ozturk B,
Buyukberber S, Kaya AO, Coskun O, Buyukberber N, Yildiz R, Benekli
M.
Opportunistic
cytomegalovirus infection in a patient receiving temozolomide for
treatment of malignant glioma.
J
Clin Neurosci.
2009 Feb 6;16(4):591-2. doi:
10.1016/j.jocn.2008.05.030. PMID:
19201195. Case report. ˍ
Biswas S, Burke A, Cherian S,
Williams D, Nicholson J, Horan G, Jefferies S, Williams M, Earl
HM, Burnet NG, Hatcher H.
Non-pineal
supratentorial primitive neuro-ectodermal tumors (sPNET) in
teenagers and young adults: Time to reconsider cisplatin based
chemotherapy after cranio-spinal irradiation?
Pediatr
Blood Cancer.
2009 Feb 7;52(7):796-803. doi:
10.1002/pbc.21899. PMID:
19202566. Observational study. ˍ
*
Quinn JA, Jiang SX, Reardon DA,
Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH,
Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A,
Friedman HS.
Phase
II trial of temozolomide plus o6-benzylguanine in adults with
recurrent, temozolomide-resistant malignant glioma.
J
Clin Oncol. 2009
Feb 9;27(8):1262-7. doi:
10.1200/JCO.2008.18.8417. PMID:
19204199. Interventional study. ˍ
van den Bent MJ, Brandes AA,
Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM,
Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A,
Kletzl H, Klughammer B, Lacombe D, Gorlia T.
Randomized
phase II trial of erlotinib versus temozolomide or carmustine in
recurrent glioblastoma: EORTC brain tumor group study 26034.
J
Clin Oncol. 2009
Feb 9;27(8):1268-74. doi:
10.1200/JCO.2008.17.5984. PMID:
19204207. Interventional study. ˍ
*
Purkayastha S, Berliner A, Fernando
SS, Ranasinghe B, Ray I, Tariq H, Banerjee P.
Curcumin
blocks brain tumor formation.
Brain
Res. 2009 Feb
11;1266:130-8. doi:
10.1016/j.brainres.2009.01.066. PMID:
19368804. Laboratory investigation. ˍ
Silvani A, Gaviani P, Lamperti EA,
Eoli M, Falcone C, Dimeco F, Milanesi IM, Erbetta A, Boiardi A,
Fariselli L, Salmaggi A.
Cisplatinum
and BCNU chemotherapy in primary glioblastoma patients.
J
Neurooncol. 2009
Feb 11;94(1):57-62. doi:
10.1007/s11060-009-9800-0. PMID:
19212704. Observational study. ˍ
Buhl R, Stark AM, Hugo HH, Rohr A,
Mehdorn HM.
Gliosarcoma:
clinical experiences and additional information with MR
spectroscopy.
Neurol
Res. 2009 Feb
12;31(8):873-7. doi:
10.1179/174313209X395490. PMID:
19215667. Observational study. ˍ
Glas M, Hundsberger T, Stuplich M,
Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger
U.
Nimustine
(ACNU) plus teniposide (VM26) in recurrent glioblastoma.
Oncology.
2009 Feb 13;76(3):184-9. doi:
10.1159/000201943. PMID:
19218824. Observational study. ˍ
*
Gerstner ER, McNamara MB, Norden
AD, Lafrankie D, Wen PY.
Effect
of adding temozolomide to radiation therapy on the incidence of
pseudo-progression.
J
Neurooncol. 2009
Feb 17;94(1):97-101. doi:
10.1007/s11060-009-9809-4. PMID:
19221865. Observational study. ˍ
Kouwenhoven MC, Gorlia T, Kros JM,
Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG,
Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L,
Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent
MJ.
Molecular
analysis of anaplastic oligodendroglial tumors in a prospective
randomized study: A report from EORTC study 26951.
Neuro
Oncol. 2009 Feb
17;11(6):737-46. doi:
10.1215/15228517-2009-011. PMID:
19224764. Interventional study. ˍ
Sawamura Y, Kamoshima Y, Kato T,
Tajima T, Tsubaki J.
Chemotherapy
with cisplatin and vincristine for optic pathway/hypothalamic
astrocytoma in young children.
Jpn
J Clin Oncol.
2009 Feb 17;39(5):277-83. doi:
10.1093/jjco/hyp012. PMID:
19224939. Observational study. ˍ
Díaz JL, Barreto P, Gallego
JM, Barbero J, Bayés R, Barcia JA.
Proper
information during the surgical decision-making process lowers the
anxiety of patients with high-grade gliomas.
Acta
Neurochir (Wien).
Feb 18;151(4):357-62. doi:
10.1007/s00701-009-0195-7. PMID:
19224120. Observational study. ˍ
Pettorini BL, Narducci A, de Carlo
A, Abet F, Caldarelli M, Massimi L, Tamburrini G, Di Rocco
C.
Thyroid
neoplasm after central nervous system irradiation for
medulloblastoma in childhood: report of two cases.
Childs
Nerv Syst. 2009
Feb 19;25(5):631-4. doi:
10.1007/s00381-009-0814-x. PMID:
19225785. Case report. ˍ
Pirzkall A, McGue C, Saraswathy S,
Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM,
Nelson SJ.
Tumor
regrowth between surgery and initiation of adjuvant therapy in
patients with newly diagnosed glioblastoma.
Neuro
Oncol. 2009 Feb
19;11(6):842-52. doi:
10.1215/15228517-2009-005. PMID:
19229057. Observational study. ˍ
Yan H, Parsons DW, Jin G, McLendon
R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins
GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW,
Velculescu VE, Vogelstein B, Bigner DD.
IDH1
and IDH2 mutations in gliomas.
N
Engl J Med. 2009
Feb 19;360(8):765-73. doi:
10.1056/NEJMoa0808710. PMID:
19228619. Laboratory investigation. ˍ
Riffaud L, Saikali S, Leray E,
Hamlat A, Haegelen C, Vauleon E, Lesimple T.
Survival
and prognostic factors in a series of adults with
medulloblastomas.
J
Neurosurg. 2009
Feb 20;111(3):478-87. doi:
10.3171/2009.1.JNS081004. PMID:
19231932. Observational study. ˍ
James CD, Cavenee WK.
Stem cells for
treating glioblastoma: how close to reality?
Neuro
Oncol. 2009 Feb 23;11(2):101. doi:
10.1215/15228517-2009-016. PMID:
19237733. Editorial. ˍ
Related
article:
Uzzaman M, Keller G, Germano IM. In
vivo gene delivery by embryonic-stem-cell-derived astrocytes for
malignant gliomas.
Neuro
Oncol.
2008 Aug 1;11(2):102-8. doi:
10.1215/15228517-2008-056. PMID:
18676359. Laboratory investigation. ˍ
Barzon L, Pacenti M, Franchin E, Colombo F, Palù
G.
HSV-TK/IL-2 gene therapy
for glioblastoma multiforme.
Methods
Mol Biol. 2009 Feb 24;542:529-49. doi:
10.1007/978-1-59745-561-9_28. PMID:
19565921. Intervenional study protocol. ˍ
Chamberlain MC.
Bevacizumab for
recurrent malignant gliomas: efficacy, toxicity, and patterns of
recurrence.
Neurology.
2009 Feb 24;72(8):772-3. doi:
10.1212/01.wnl.0000339387.03225.0a. PMID:
19237713. Comment. ˍ
Related
article:
Norden AD, Young GS, Setayesh K, et al. Bevacizumab
for recurrent malignant gliomas: efficacy, toxicity, and patterns
of recurrence.
Neurology.
2008 Mar 4;70(10):779-87. doi:
10.1212/01.wnl.0000304121.57857.38. PMID:
18316689. Observational study. ˍ
Uziel T, Karginov FV, Xie S, Parker
JS, Wang YD, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G,
Roussel MF.
The
miR-17~92 cluster The miR-17~92 cluster collaborates with the
Sonic Hedgehog pathway in medulloblastoma.
Proc
Natl Acad Sci USA.
2009 Feb 24;106(8):2812-7. doi:
10.1073/pnas.0809579106. PMID:
19196975. Laboratory investigation. ˍ
Henke G, Paulsen F, Steinbach JP,
Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka
C.
Hypofractionated
reirradiation for recurrent malignant glioma.
Strahlenther
Onkol. 2009 Feb
25;185(2):113-9. doi:
10.1007/s00066-009-1969-9. PMID:
19240998. Observational study. ˍ
Wick A, Pascher C, Wick W, Jauch T,
Weller M, Bogdahn U, Hau P.
Rechallenge
with temozolomide in patients with recurrent gliomas.
J
Neurol. 2009 Feb
25;256(5):734-41. doi:
10.1007/s00415-009-5006-9. PMID:
19240962. Observational study. ˍ
Reardon DA, Egorin MJ, Desjardins
A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon
JE 2nd, Salvado AJ, Friedman HS.
Phase
I pharmacokinetic study of the vascular endothelial growth factor
receptor tyrosine kinase inhibitor vatalanib (PTK787) plus
imatinib and hydroxyurea for malignant glioma.
Cancer.
2009 Feb 26;115(10):2188-98. doi:
10.1002/cncr.24213. PMID:
19248046. Interventional study. ˍ
von Hoff K, Hinkes B, Gerber NU,
Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M,
Soerensen N, Zwiener I, Goette H, Schlegel PG, Pietsch T, Kortmann
RD, Kuehl J, Rutkowski S.
Long-term
outcome and clinical prognostic factors in children with
medulloblastoma treated in the prospective randomised multicentre
trial HIT'91.
Eur
J Cancer. 2009
Feb 26;45(7):1209-1217. doi:
10.1016/j.ejca.2009.01.015. PMID:
19250820. Interventional study. ˍ
*
Watanabe T, Nobusawa S, Kleihues P,
Ohgaki H.
IDH1
mutations are early events in the development of astrocytomas and
oligodendrogliomas.
Am
J Pathol. 2009
Feb 26;174(4):1149-53. doi:
10.2353/ajpath.2009.080958. PMID:
19246647. Laboratory investigation. ˍ
Lomonaco SL, Finniss S, Xiang C,
Decarvalho A, Umansky F, Kalkanis SN, Mikkelsen T, Brodie C.
The
induction of autophagy by gamma-radiation contributes to the
radioresistance of glioma stem cells.
Int
J Cancer. 2009
Feb 27;125(3):717-22. doi:
10.1002/ijc.24402. PMID:
19431142. Laboratory investigation. ˍ
Yamasaki F, Sugiyama K, Ohtaki M,
Takeshima Y, Abe N, Akiyama Y, Takaba J, Amatya VJ, Saito T,
Kajiwara Y, Hanaya R, Kurisu K.
Glioblastoma
treated with postoperative radio-chemotherapy: prognostic value of
apparent diffusion coefficient at MR imaging.
Eur
J Radiol. 2009
Feb 27;73(3):532-7. doi:
10.1016/j.ejrad.2009.01.013. PMID:
19250783. Observational study. ˍ